Mission Bio

Today, we're thrilled to announce the Tapestri Single-cell Multiple Myeloma Multiomics Solution! 🎉 This groundbreaking product suite is set to transform MM research and therapeutic development, offering unparalleled insights into disease evolution and biology at the single-cell level. 🔬 Our new solution integrates genomic, proteomic, and clonotypic assessments in a single assay, providing comprehensive clonal and subclonal insights that surpass existing bulk methodologies. This will empower researchers and drug developers to fully dissect the molecular and cellular landscape of myeloid progression, understand therapy resistance, and address disease relapse more effectively. Stay tuned for more details, including late-breaking data to be presented at the European Hematology Association (EHA) Congress on June 14. 📅 Check out our press release to learn more https://bit.ly/4e9AEtE #multiplemyeloma #singlecell #multiomics #pressrelease #eha2024

Next week, join our own Stéphane COLINET for an informative presentation at Paris Saclay Cancer Cluster (PSCC)! Stéphane will be discussing how DNA single-cell analysis can resolve understanding of cancer diseases and the therapeutic strategies to improve clinical outcomes. 📅 Tuesday, December 17 | 8.45a Register here 👉 https://lnkd.in/eNsz_2Eb

We're in the home stretch of #ASH24! We've had an amazing few days in San Diego - but it's not over yet! Visit us at Booth #2112 to meet our team and see the Tapestri Platform in action 💥 Didn't make it to ASH this year? Learn more about how our customers are utilizing single-cell multiomics to transform their research here 👉 https://lnkd.in/gYEunKmw

Day 2 of #ASH24 is going strong and Booth #2112 is buzzing! 🐝 🐝 🐝 Drop by and visit our team to learn more about how single-cell multiomics can unlock insights for AML, Multiple Myeloma, and more. Don't just take our word for it - with 24+ posters and oral presentations utilizing Mission Bio technology and the Tapestri Platform, you can gain real-world insight into how our customers are supercharging their research 💪 Learn more here: https://lnkd.in/g8uEeEbc

And we're off! 🏃♂️ 🏃♀️ 💨 #ASH24 is in full swing and we're having a blast in sunny San Diego! Visit the Mission Bio team at Booth #2112 to say hello and learn how you can leverage the Tapestri Platform to gain a deeper understanding of Multiple Myeloma, AML, Lymphoma, and CAR-T therapy development.

✨ #ASH24 Abstract Highlight ✨ In this study led by Edward Ayoub, researchers from MD Anderson Cancer Center were able to establish a genotype-phenotype connection through single-cell multiomic profiling of TP53-mutated AML and map the clonal evolution and immunophenotypic dynamics during treatment. 🗣️ Oral 61: Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones 📅 Saturday, December 7 | 9:30a PT Get the full list of posters and presentations or book a meeting with our team at ASH 👉 https://lnkd.in/gYEunKmw

Looking good crew! Our Mission Bio team is having a great time at the 6th Annual Cell Therapy Analytical Development Summit in Boston! If you're attending, be sure to check out Nori U.'s presentation tomorrow ⤵️ 🧬 “Single-Cell Multi-omic Assessment of Gene Editing Outcomes, Toxicity, & VCN for High Resolution Characterization of Cell Therapies” 📅 Thursday, December 5 | 12p ET And check out our posters too! ⤵️ ✅ Single-cell Multi-omics Analysis Reveals Differential Lineage-specific Vector Copy Number Distribution in CAR-T Cell Products ➡️ https://lnkd.in/g9-VaP3n ✅ High Throughput Single-cell Assessment of Genome Integrity and Toxicity Events Associated With Edited Cells ➡️ https://lnkd.in/gTBHr7Gj

✨ #ASH24 Abstract Highlight ✨ In this oral presentation, hear from researchers from the lab of Linde A. Miles on how single-cell multiomics was utilized to co-detect KMT2A fusion transcripts, somatic mutations, and targeted gene expression. 🗣️ Oral 66: Single-Cell Multi-Omic Analysis of KMT2A-Rearranged Pediatric Acute Leukemia Clonal Evolution 📅 Saturday, December 7 | 10:45a PT Get the full list of posters and presentations or book a meeting with our team at ASH 👉 https://lnkd.in/gYEunKmw

Exciting news! Just announced today, Mission Bio will be collaborating with Dr. C. Ola Landgren, MD, PhD, & team at the University of Miami's Sylvester Comprehensive Cancer Center to better understand multiple myeloma relapse. Dr. Landgren's team will work together to generate clinical data sets using the Tapestri Single-cell DNA Multiple Myeloma Panel to examine MM at an unprecedented level of clonal detail, promising to reveal new insights that may potentially improve outcomes for MM patients. “Our aim is to utilize Tapestri to better understand Multiple Myeloma disease heterogeneity, which in turn will allow us to detect and treat relapse faster. Ultimately, we hope to demonstrate the clinical feasibility of the Multiple Myeloma assay and to facilitate the establishment of Tapestri to advance outcomes for patients.” - Dr. C. Ola Landgren Read more about this exciting collaboration here 👉 https://bit.ly/41egMlf

In anticipation of #ASH24 right around the corner, we'll be highlighting a few exciting poster and oral presentations that utilize Mission Bio technology! Our first poster highlight comes from researchers at the University of Miami Miller School of Medicine, where they utilized the Tapestri scMRD Assay for AML to assess a prospective cohort of AML patients - gaining genotypic and phenotypic insights missed by bulk sequencing. 🗒️ Poster 4333: Clinical Application of Single-Cell MRD By Genotype and Phenotype in AML 📅 Monday, December 9 | 6-8p PT Get the full list of posters and presentations or book a meeting with our team at ASH 👉 https://lnkd.in/gYEunKmw